UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) ~~April~~August 9, 2010

HEMOBIOTECH, INC.

------------------------------------------------------

(Exact Name of Registrant as Specified in Its Charter)

DELAWARE

(State or Other Jurisdiction of Incorporation)

----------------------------------------------

000-51334		33-0995817
(Commission File Number)		(IRS Employer Identification No.)

(State or Other Jurisdiction of Incorporation)

000-51334 33-0995817

------------------------ ---------------------------------

(Commission File Number) (IRS Employer Identification No.)

5001 Spring Valley Road, Ste 1040-West

Dallas, TX 75244

(Address of Principal Executive Offices) (Zip Code)

--------------------------------------------------------

(Address of Principal Executive Offices) (Zip Code)

(972) 455-8950

----------------------------------------------------

(Registrant's Telephone Number, Including Area Code)

-------------------------------------------------------------

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~ITEM 4~~Item 5.0102. ~~CHANGES~~Departure INof ~~REGISTRANT'S~~Directors ~~CERTIFYING~~or ~~ACCOUNTANT~~Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(ab) ~~Effective as~~ ofOn ~~April~~August 9, 2010, ~~upon~~Dr. ~~the~~Arthur ~~authorization~~P. ~~and~~Bollon ~~approval~~resigned ofas ~~its~~President ~~Board~~and Chief Executive Officer of ~~Directors,~~ HemoBioTech, Inc., ~~a Delaware corporation~~ (the “~~Registrant~~Company”) ~~dismissed Eisner~~in ~~LLP~~order asto ~~its~~pursue other opportunities. He will remain an independent ~~registered~~director ~~public~~and ~~accounting~~a ~~firm~~consultant to the Company.

~~The reports~~(c) ofOn ~~Eisner~~August ~~LLP~~9, on2010, the ~~financial~~Board ~~statements~~ of ~~the~~Directors ~~Registrant as~~ of ~~and for~~ the ~~fiscal years ended December 31~~Company, ~~2008~~appointed ~~and~~Robert ~~2007~~E. ~~and for the period from October 3~~Dragoo, ~~2001~~Jr. ~~(inception)~~as ~~through~~Interim ~~December~~Chief ~~31,~~Executive ~~2008~~Officer. ~~did~~Mr. ~~not~~Dragoo ~~contain~~is an ~~adverse opinion~~independent ordirector ~~disclaimer~~ of ~~opinion, nor were they qualified or modified as to audit scope, or accounting principles, except that~~ the ~~Registrant’s~~Company ~~audited financial~~who ~~statements~~will ~~contained~~serve inuntil ~~its~~a ~~Form~~search ~~10-K~~committee ~~for~~is ~~the~~able ~~fiscal~~to ~~years~~retain ~~ended December 31, 2008 and 2007 and for~~ the ~~period~~services ~~from~~of ~~October 3, 2001 (inception) through December 31, 2008 included explanatory language concerning the Registrant’s ability to continue as~~ a ~~going~~permanent ~~concern~~CEO.

~~During~~Robert E. Dragoo, Jr., age ~~the~~70, has ~~fiscal~~served ~~years~~as ~~ended~~a director ~~December~~since 31January 28, ~~2008~~2009. ~~and~~Mr. ~~2007,~~Dragoo ~~and~~previously ~~through~~served ~~April~~as 9,the ~~2010,~~Chief ~~there~~Operating ~~were~~Officer ~~(i)~~and noSenior ~~disagreements~~Vice ~~with~~President ~~Eisner~~for ~~LLP~~Administration onand ~~any~~Finance ~~matter~~at Texas Tech University which is a significant shareholder of ~~accounting~~the ~~principles~~Company. orPrior ~~practices,~~to ~~financial~~Texas ~~statement disclosure~~Tech, orMr. ~~auditing~~Dragoo ~~scope~~was ~~or procedure,~~a ~~which~~Senior ~~disagreements,~~Vice ifPresident ~~not~~for ~~resolved~~Temple Inland toCorporation ~~the~~and ~~satisfaction~~is ofa ~~Eisner LLP,~~former ~~would~~Senior ~~have~~Partner ~~caused~~of ~~Eisner~~Ernst ~~LLP~~and toYoung’s ~~make~~Center for ~~reference~~Business ~~thereto~~Innovation located in ~~its~~Cambridge ~~reports~~Mass. ~~on the~~Mr. ~~Company’s~~Dragoo ~~financial~~has ~~statements~~over ~~for~~35 ~~such~~years experience ~~fiscal~~in ~~years;~~business management and ~~(ii)~~business noperformance ~~reportable events~~improvement. asHe ~~set~~holds a ~~forth~~B.S. in Mechanical ~~Item~~Engineering ~~304(a)(1)(v)~~from ofTexas Tech University, ~~Regulation~~and completed ~~S-K~~an Executive MBA program at Harvard University.

~~The Registrant~~There ~~provided~~were ~~Eisner~~no ~~LLP~~transactions ~~with a copy of the disclosures made above in~~since ~~response~~January to1, ~~Item~~2009, ~~304(a)~~or ofany ~~Regulation~~currently ~~S-K~~proposed ~~and~~transactions ~~requested~~between ~~that Eisner LLP furnish it with a letter addressed to~~ the ~~Securities~~Company ~~and Exchange Commission (the~~in ~~“Commission”)~~which ~~stating whether or not it agrees with the above statements~~Mr. ~~The~~ ~~Company~~Dragoo ~~has~~had ~~received~~ a ~~letter~~direct ~~from~~or ~~Eisner~~indirect ~~LLP addressed~~material ~~to the Securities and Exchange Commission dated April 12, 2010 indicating that it agreed with the statements set forth above~~interest. ~~A copy of that letter dated as of April 12, 2010, is attached hereto as Exhibit 16.1.~~

~~(b) Effective~~Item ~~as of April~~ 9,.01 ~~2010,~~Financial ~~upon~~Statements ~~the authorization~~ and approval of the Audit Committee of its Board of Directors, the Registrant engaged M&K CPAs, PLLC as its independent registered public accounting firm. M&K CPAs, PLLC was engaged to also re-audit the Registrant’s financial statements for the year ended December 31, 2008.Exhibits

No consultations occurred between the Registrant and M&K CPAs, PLLC during the fiscal years ended December 31, 2008 and 2007, through April 9, 2010, regarding either (1) the application of accounting principles to a specific completed or contemplated transactions, the type of audit opinion that might be rendered on the Registrant’s financial statements, or other information provided that was an important factor considered by the Registrant in reaching a decision as to an accounting, auditing, or financial reporting issue, or (ii) any matter that was the subject of disagreement or a reportable event requiring disclosure under Item 304(a)(1)(iv) or (v), respectively, of Regulation S-K.None

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

d) Exhibits

No. Exhibits

----- -----------------------

16.1 Letter from Eisner LLP, dated April 12, 2010, to the Commission regarding statements included in this Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 13, 2010 HEMOBIOTECH, INC.

Date: August 13, 2010	HEMOBIOTECH, INC.


	By: /s/ Robert Baron
	Name: Robert Baron
	Title: Chairman of the Board

By: /s/ Arthur P. Bollon__________________

Name: Arthur P. Bollon, Ph.D.

Title: Chief Executive Officer and President

EXHIBIT INDEX

Exhibit No. Description of Exhibit

-------------- ---------------------------------------

16.1 Letter from Eisner LLP, dated April 12, 2010, to the Commission regarding statements included in this Form 8-K

Filing Compare · HEMOBIOTECH, INC.